[ad_1]
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
* Continues to build on Sanofi’s leading presence in immunology, in line with its strategy to pursue best-in-class treatments in defined areas
PARIS and CAMBRIDGE, United Kingdom – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies focused on immune-mediated diseases and immuno-oncology therapies, have entered into an agreement whereby Sanofi will acquire Kymab for an upfront payment of approximately $ 1, $ 1 billion and up to $ 350 million when reaching certain milestones.
The transaction will give Sanofi full worldwide rights to KY1005, a fully human monoclonal antibody with a new mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders.
“The acquisition of Kymab adds KY1005 to our dynamic pipeline, a potential first-rate treatment for a range of immune and inflammatory diseases. The new mechanism of action can provide treatment to patients whose responses are not optimal to available therapies ”. said Paul Hudson, CEO of Sanofi. “We understand from our ongoing work on immunologic debilitating diseases how critical it is to find the right treatment for each patient. We look forward to rapidly developing this experimental medicine.
“The the agreement testifies to the the commitment, dynamism and expertise of the entire Kymab team and we are delighted to receive this Sanofi approval, ” added Simon Sturge, CEO of Kymab. “With his important global resources, wbelieve herdost is the perfect partner to advance Kymab’s product pipeline and the merger will speed up time it is necessarys for our new therapies at reach patients. “
KY1005: promising antibody for inflammatory disorders
In August 2020, Kymab announced that KY1005 met the two primary endpoints in a phase 2a trial studying patients with moderate to severe atopic dermatitis whose disease is insufficiently controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect compared to placebo on a variety of key parameters including eczema area and severity index (EASI) and additional objective clinical measures.
“This acquisition is part of our strategy of targeting pathological pathways of fundamental importance. We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, offering a promising new approach to treat a range of immune-mediated diseases ”. said John Reed, MD Ph.D., global head of research and development at Sanofi.
Kymab’s pipeline also includes the oncological active KY1044, an ICOS agonist monoclonal antibody, currently in early development phase 1/2 as monotherapy and in combination with an anti-PD-L1. This acquisition also gives Sanofi access to new antibody technologies and research capabilities.
Transaction conditions
Under the terms of the transaction, Sanofi will acquire Kymab for an upfront payment of approximately $ 1.1 billion and up to $ 350 million upon reaching certain milestones.
Sanofi plans to finance the transaction with cash. Closing of the transaction is subject to the expiration or end of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Sanofi plans to complete the acquisition in the first half of 2021.
Weil, Gotshal & Manges LLP acts as legal counsel to Sanofi. JP Morgan is acting as financial advisor to Kymab and Goodwin PLC is acting as legal advisor.
About Kymab
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapies with a focus on immune-mediated diseases and immuno-oncology using its proprietary integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect transgenic platforms contain a wide variety of human antibodies, making them the most comprehensive antibody platforms available.
Selection from a wide variety of fully human antibodies ensures the greatest likelihood of quickly and efficiently finding drug candidates with best-in-class characteristics.
For more information on Kymab, please see http://www.kymab.com. Kymab and IntelliSelect are registered trademarks of Kymab Limited.
|
About Sanofi Sanofi is dedicated to supporting people in their health challenges. We are a global biopharmaceutical company focused on human health. We prevent disease with vaccines, offer innovative treatments to fight pain and relieve suffering. We support the few people who suffer from rare diseases and the millions of people with long-term chronic diseases. With more than 100,000 people in 100 countries, Sanofi transforms scientific innovation into healthcare solutions around the world. Sanofi, empowering life |
|
| Sanofi media relations contacts Ashleigh Koss Phone: +1 (908) 205 2572 [email protected] Quentin Alive Kymab Brandon lewis |
Investor Relations Contacts Sanofi Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne naughton Contacts Investor Relations Sanofi North America IR main line: Kymab Media UK Mary-Jane Elliott / Sukaina Virji / Melissa Gardiner Phone: +44 (0) 20 3709 5700 |
| Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will” and similar expressions. Although Sanofi management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. which could cause actual results and developments to differ materially from those expressed, implied or projected by forward-looking information and statements. These risks and uncertainties include, among others, risks relating to Sanofi’s ability to complete the acquisition on the terms proposed or according to the proposed schedule, including obtaining the required regulatory approvals, other risks associated with the execution. business combination transactions, such as the risk that companies will not be integrated successfully, that such integration could be more difficult, time-consuming or expensive than expected or that the expected benefits of the acquisition will not materialize, including the ability to develop, market or commercialize new products, competition, uncertainties inherent in research and development, including future clinical data and analyzes, regulatory obligations and oversight by regulatory authorities, such as the FDA or EMA, including decisions by those authorities regarding the approval and timing of approval of any m drug, device or biological application that could be filed for any product candidate as well as decisions regarding labeling and other matters which could affect the availability or commercial potential of any product candidate, the lack of guarantee that any product candidate , if approved, will experience commercial success, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and to complete related transactions and / or obtain regulatory authorizations , the risks associated with the intellectual property of Sanofi and Kymab and any related pending or future litigation and the ultimate outcome of such litigation, trends in prevailing exchange rates and interest rates, and market conditions, cost containment initiatives and their subsequent modifications, and the impact that COVID-19 will have on Sanofi and Kymab and their customers, issuers, vendors and other respective business partners, as well as the financial condition of any of them, as well as the employees of Sanofi and Kymab and the world economy as a whole. Any significant effect of COVID-19 on any of the above could also negatively impact Sanofi and Kymab. This situation is changing rapidly and additional impacts may arise, of which Sanofi and Kymab are not currently aware, and may exacerbate other previously identified risks. Although the list of factors presented here is representative, no list should be taken as a statement of all the potential risks, uncertainties or assumptions that could have a material adverse effect on Sanofi’s consolidated financial position or results of operations. The above factors should be read in conjunction with the risks and caveats discussed or identified in public documents filed with the Securities and Exchange Commission (the “SEC”) and the AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in Sanofi’s Annual Report on Form 20-F for the year ended December 31, 2019 and in subsequent Form 6-K filed with the SEC. Forward-looking statements speak only as of the date hereof and, except as required by applicable law, Sanofi undertakes no obligation to update or revise forward-looking information or statements. |
|
[ad_2]
Source link